This study is testing a cream called ruxolitinib to see if it helps adults with moderate Atopic Dermatitis (AD), a condition that makes skin itchy and red. The study is for people who didn't have good results with other creams or can't use them.

• Study Length: The study requires regular visits and using the cream as instructed.
• Compensation: Participants may receive compensation for their time and travel.
• Risks: Possible skin reactions or other side effects.

To join, participants must be 18 or older and have had AD for at least 2 years. They should also meet certain scores and have tried other treatments without success. People with unstable AD or certain other conditions, like infections or liver problems, can't join. The study has rules about stopping other AD treatments during the trial. Participants must agree not to become pregnant or father a child while in the study. Some conditions, like certain infections or recent use of specific medications, might exclude someone from taking part. Always discuss with a doctor to understand if joining is suitable for you.